Eledon Pharmaceuticals, Inc. — Director's Dealing 2017

May 12, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Novus Therapeutics, Inc. (NVUS)
CIK: 0001404281
Period of Report: 2017-05-10

Reporting Person: Chimovits Erez (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2537110	Indirect

Footnotes

F1: All numbers give effect to the 1:9 reverse stock split effected by the Issuer on May 11, 2017.

F2: The Reporting Person is the designated representative of OrbiMed Israel GP Ltd. on the Issuer's Board of Directors. The reportable securities are owned directly by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any.